Funding for this research was provided by:
The University of Queensland
Article History
Accepted: 4 April 2022
First Online: 31 May 2022
Declarations
:
: WX reports personal fees and non-financial support from Merck Serono, MSD and AZ and is on advisory boards for Merck Serono, MSD and Novartis. VA reports personal fees from BMS, MSD, Novartis, Limbic and Pierre Fabre and is on advisory boards for BMS, MSD, Novartis, NEKTAR, Q Biotics, Limbic and Pierre Fabre. GN has declared no conflicts of interest.